top of page
.png)
FDA grants fast track designation to HLD-0915 in mCRPC
9/17/25, 9:00 PM
Preclinical studies demonstrated tumor shrinkage and PSA decline with HLD-0915, showing a favorable therapeutic index, even in drug-resistant models.
bottom of page
9/17/25, 9:00 PM
Preclinical studies demonstrated tumor shrinkage and PSA decline with HLD-0915, showing a favorable therapeutic index, even in drug-resistant models.